Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2010

Cypress Bioscience Spurns Ramius' Buyout Offer

  • The board of directors at Cypress Bioscience has rejected an unsolicited, nonbinding proposal by Ramius to acquire all of the outstanding shares of Cypress common stock not owned by Ramius for $4.00 per share in cash. The board unanimously agreed that the bid grossly undervalues Cypress’ current business and future prospects and consequently is not in the best interests of Cypress’ other stockholders.

    Yesterday the company reported two cost-cutting measures that will reportedly save it over $10 million per year. In addition to passing all U.S. marketing rights to its fibromyalgia drug Savella® over to current U.S. co-marketing partner Forest Laboratories, Cypress also confirmed that it aims to either discontinue or sell its personalized medicine services business and slash its workforce by 86%. Cypress’ stock has dropped 37% over the last 52-week period, and currently sits at around $3.54 per share, with a 52-week high of $9.45 and a low point of $2.06. The firm recorded a net deficit of $28.25 million for the year ended December 31, 2009, on total revenues of $27.33 million. Cypress has a current market cap of some $139.3 million.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »